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Neurobiology of Disease

Dopamine-Dependent Compensation Maintains Motor
Behavior in Mice with Developmental Ablation of
Dopaminergic Neurons
Judith P. Golden,1 Joseph A. DeMaro III,1 Amanda Knoten,2 Masato Hoshi,2 Elizabeth Pehek,7,8
Eugene M. Johnson, Jr.,3,4,5 Robert W. Gereau IV,1,3 and Sanjay Jain2,3,6
1

Washington University Pain Center, Department of Anesthesiology, 2Department of Medicine, Renal Division, 3Hope Center for Neurological Disorders,
Department of Neurology, 5Department of Developmental Biology, 6Department of Pathology and Immunology Research, Washington University School
of Medicine, St. Louis, Missouri 63110, 7Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio 44106, and 8Departments of Psychiatry and
Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106
4

The loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and consequent depletion of striatal dopamine are known
to underlie the motor deficits observed in Parkinson’s disease (PD). Adaptive changes in dopaminergic terminals and in postsynaptic
striatal neurons can compensate for significant losses of striatal dopamine, resulting in preservation of motor behavior. In addition,
compensatory changes independent of striatal dopamine have been proposed based on PD therapies that modulate nondopaminergic
circuits within the basal ganglia. We used a genetic strategy to selectively destroy dopaminergic neurons in mice during development to
determine the necessity of these neurons for the maintenance of normal motor behavior in adult and aged mice. We find that loss of 90%
of SNc dopaminergic neurons and consequent depletion of ⬎95% of striatal dopamine does not result in changes in motor behavior in
young-adult or aged mice as evaluated by an extensive array of motor behavior tests. Treatment of aged mutant mice with the dopamine
receptor antagonist haloperidol precipitated motor behavior deficits in aged mutant mice, indicating that ⬍5% of striatal dopamine is
sufficient to maintain motor function in these mice. We also found that mutant mice exhibit an exaggerated response to L-DOPA
compared with control mice, suggesting that preservation of motor function involves sensitization of striatal dopamine receptors. Our
results indicate that congenital loss of dopaminergic neurons induces remarkable adaptions in the nigrostriatal system where limited
amounts of dopamine in the dorsal striatum can maintain normal motor function.

Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder, affecting 1% of the population ⬎60 years of
age. Progressive degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNc) and resultant depletion of
dopamine from the striatum underlie the motor behavior deficits
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age to the nigrostriatal pathway (Dauer and Przedborski, 2003).
Although the central role of midbrain dopaminergic neurons in
the pathogenesis of PD is well established, efforts to rescue degenerating SNc dopaminergic neurons in PD patients have been
unsuccessful. Alternative strategies that bypass dopaminergic
neuron function by altering activity of basal ganglia circuits independently of dopamine, such as deep-brain stimulation of the
subthalamic nucleus or globus palidus (Ponce and Lozano, 2010)
or antagonism of A2 adenosine receptors (Hickey and Stacy,
2012), have shown efficacy in relieving the motor symptoms of
PD. These findings suggest that basal ganglia function can be
restored independently of SNc dopaminergic neurons.
Motor behavior changes resulting from damage to dopaminergic neurons during development are of interest for several
reasons. First, 6-hydroxydopamine (6-OHDA) administered to
neonatal rats results in near complete depletion of striatal
dopamine but produces less severe deficits in motor behavior
compared with adult animals sustaining damage of the same
magnitude (Breese et al., 2005). The mechanism underlying this
behavior sparing is reportedly independent of dopamine (Bruno
et al., 1985; Duncan et al., 1987). Thus, animal models in which
dopamine is severely depleted during development provide an
opportunity to study potential nondopaminergic mechanisms of
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plasticity in developing dopaminergic circuits. Animal models in
which developmental damage to dopaminergic neurons is moderate are also of significant interest. Partial damage to the nigrostriatal pathway resulting from prenatal or early postnatal
exposure to toxins renders mice more vulnerable to dopaminergic neuron damage later in life and has been proposed to predispose humans to PD (Carvey et al., 2003; Bakos et al., 2004; Barlow
et al., 2007; Muthian et al., 2010). These studies have provided
important insights into the effects of developmental damage of
dopaminergic neurons on motor behavior and on increased vulnerability of dopaminergic neurons to a second toxin treatment
in adulthood. However, the use of exogenous toxins to destroy
dopaminergic neurons during development is limited by a number of factors, including uncertain specificity of the toxins and
dosing limitations necessitated by the potential for systemic toxicity to pregnant animals. Models that avoid these confounds
have the potential to provide new insights into the consequences
of developmental dopaminergic neuron damage and into the
mechanisms underlying plasticity in the developing nigrostriatal
system.
Here we expressed diphtheria toxin in dopaminergic neurons
to create a model of developmental damage that is specific for
dopaminergic neurons. A broad spectrum of motor behavior
tests demonstrated that, surprisingly, near complete loss of striatal dopamine produced no detectable motor behavior deficits in
adult or aged mutant mice. Transient blockade of dopaminergic
transmission using haloperidol precipitated motor dysfunction
in mutant mice indistinguishable from that seen in control mice,
indicating that the small amount of residual dopamine present in
the striatum of these mice is sufficient to maintain normal motor
function. In addition, mutant mice show increased locomotor behavior in response to L-DOPA at a dose that does not alter locomotor
activity in control mice, suggesting that the mechanism by which
motor behavior is preserved in DAT-DTA (Dopamine transporterCreRosafloxSTOPfloxdta) mice involves functional sensitization of striatal dopamine receptors.

Materials and Methods
Animal generation. Institutionally approved protocols were followed for
all animal studies. To generate mice with conditional expression of attenuated diphtheria toxin (DTA) in dopaminergic neurons, mice expressing DTA from the Rosa locus (RosafloxSTOPfloxdta/ ⫹) (Wu et al.,
2006) were crossed with heterozygous mice expressing Cre from the
dopamine transporter (DAT) locus (DATCre/⫹; Zhuang et al., 2005; Fig.
1A). These experimental mice are hereafter referred to as DAT-DTA
mice (RosafloxSTOPfloxdta/⫹:DATCre/⫹). Control mice used in this study are
littermates or age-matched mice that have one DTA allele but no Cre
allele (RosafloxSTOPfloxdta/⫹:DAT⫹/⫹). Previous studies have found no difference in locomotor activity in DAT⫹/ ⫺ and wild-type mice (Giros et
al., 1996).
Behavior testing. Behavior testing was performed using male and female mice from 1.5 to 24 months of age. The experimenter was blind to
the genotypes of the mice and to drug treatment during data acquisition.
Gross motor function (Rotarod). An accelerating Rotarod (Ugo Basile)
was used to evaluate motor coordination and balance. Five consecutive
acceleration trials were performed with a 5 min interval between trials as
described previously (Montana et al., 2009).
Sensorimotor battery. Tests in the sensorimotor battery were used as
previously described to evaluate balance, strength, coordination, and
skilled forelimb use (Jain et al., 2006; Meredith and Kang, 2006). In
addition, we evaluated movement initiation by measuring the time it
took a mouse to exit an 18 ⫻ 18 cm square (all four paws outside the
square) marked on a flat horizontal surface.
Locomotor activity (open field). Locomotor activity was measured in an
open field using a VersaMax Animal Activity Monitoring System (Ac-
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cuScan Instruments). Mice were habituated to the test room in their
cages for 1 h before testing. Locomotor activity was assessed by recording
photo beam breaks in a 42 (length) ⫻ 42 (width) ⫻ 30 (height) cm
chamber for 60 min. Total distance traveled, time spent moving, and the
number of beam breaks (horizontal activity) were calculated for the entire chamber.
Gait analysis. Mice were trained to walk down a narrow walkway (1
m ⫻ 6.5 cm) leading to a dark box. Following training, the walkway was
covered with plain white paper and ink was applied to the hindpaws by
pressing the mouse’s foot onto an ink pad. Toe spread (TS), intertoe
spread (ITS), stride width (SW), and stride length (SL) were measured as
previously described (Taylor et al., 2001). For each mouse, a minimum of
two footprints (TS and ITS) or two sets of prints (SW and SL) were
measured for each parameter.
Haloperidol treatment. Twelve-month-old control mice and DATDTA mice were given a single intraperitoneal injection of haloperidol
(Sigma-Aldrich) dissolved in DMSO at a dose of 1 mg/kg. Ten minutes
after administration of haloperidol, movement initiation was evaluated
as described above. Catalepsy was evaluated by measuring the time required for the mouse to step down after its front or hindpaws were placed
on a 3 cm block (Weihmuller and Bruno, 1989; Mohajjel Nayebi, 2010).
Following these two tests (⬃15 min after haloperidol administration),
mice were tested in the open field (as above). Following the measurement
of open-field activity (⬃80 min after haloperidol administration) movement initiation and catalepsy were again evaluated.
Assessment of possible hypersensitivity to dopamine. Six-to-sevenmonth-old control and DAT-DTA mice were given a single intraperitoneal injection of L-DOPA (25 mg/kg) and carbidopa (10 mg/kg; both
drugs obtained from Sigma-Aldrich) dissolved in PBS containing 0.25%
ascorbic acid. Ten minutes after administration of L-DOPA, movement
initiation was evaluated as described above. Following this test (⬃15 min
after L-DOPA administration) mice were tested in the open field (as
above). After the measurement of open-field activity (⬃80 min after
L-DOPA administration) movement initiation was again evaluated.
Quantitative real-time PCR. RNA was purified from dorsal striatum from
12-month-old DAT-DTA (N ⫽ 9) and control (N ⫽ 7) mice. RNA (1 g)
was reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen).
Quantitative real-time PCR (qRT-PCR) was performed using Fast SYBR
Green Master Mix (Applied Biosystems) and reactions were run in an Applied Biosystems 7900HT Real Time Thermal Cycler. All reactions were run
in triplicate and relative fold changes in RNA amount were calculated by the
⌬⌬CT method using GAPDH to normalize samples (Livak and Schmittgen,
2001). qRT-PCR primers were designed by Primer Express software
(Applied Biosystems). Primer sequences are as follows (5⬘33⬘): D1:
forward-GCCATTCTGCATTGATTCCA, reverse-ATTCGCCCAGCCAAACC; D2: forward-CGTTATCATGAAGTCTAATGGGAGTTT,
reverse-GGCGGGCAGCATCCA.
Immunohistochemistry. At the conclusion of behavior analysis, mice
were deeply anesthetized and perfused through the heart with PBS
followed by 4% paraformaldehyde in PBS. Brains were removed immediately after perfusion, postfixed overnight in paraformaldehyde, cryoprotected with 30% sucrose, and rapidly frozen on dry ice. Brains from
postnatal day 0 (P0) mice were sectioned in the coronal plane at 20 m
and were collected in series on slides. For 1.5–12-month-old mice, 40 m
coronal brain sections were collected in PBS. Free-floating (1.5–12month-old mice) coronal sections or slides with coronal sections (P0
mice) of midbrain and striatum were labeled with an antibody to tyrosine
hydroxylase (TH; Millipore Bioscience Research Reagents) as previously
described (Jain et al., 2006). TH-labeled neurons in the SNc and the
ventral tegmental area (VTA) were counted in every fourth section by an
investigator blinded to genotype. Profiles identified as neurons were THpositive profiles that contained a nucleus and at least one process. The
total number of neurons was determined by multiplying the number of
neurons counted by four. The entire SNc and VTA were included. For
SNc counts, all sections from Plate 52-63 (Franklin and Paxinos, 1997)
were included. For VTA counts, all sections from Plate 55-63 were included. The border between the SNc and VTA was determined in each
section according to the borders outlined for these structures in the
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Figure 1. Dramatic loss of SNc and VTA neurons in DAT-DTA mice. A, Schematic illustrating breeding strategy to produce DAT-DTA mice. B, C, Weight of male and female DAT-DTA and control
mice. Female DAT-DTA mice weigh significantly less than control mice at 3–5 and 10 –21 months. Male DAT-DTA mice weigh significantly less than control mice at 10 –21 months (mean ⫾ SEM,
Student’s t test, control vs DAT-DTA at each time point; *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001). D, Loss of TH-positive neurons in the ventral midbrain of DAT-DTA mice. The number of TH-positive
neurons is significantly decreased in the SNc and VTA of DAT-DTA mice compared with control mice at all ages studied (mean ⫾ SEM, Student’s t test, control vs DAT-DTA at each time point; *p ⬍
0.05, **p ⬍ 0.01, ***p ⬍ 0.001). P0, N ⫽ 3 of each genotype; 1.5 months, N ⫽ 2 of each genotype; 5 months, N ⫽ 4 of each genotype; 12 months, N ⫽ 3 of each genotype. E, F, Nissl-labeled
coronal brain sections from 5-month-old mice showing large neurons in the SNc of control mice (E, arrows). These large neurons are absent in the SNc of DAT-DTA mice (F, arrows).

Franklin and Paxinos Brain Atlas (Franklin and Paxinos, 1997). THpositive neurons were also counted in all of the nuclei of the hypothalamus, in the dorsal thalamus, and in the periaqueductal gray of the same
5-month-old control and DAT-DTA mice used for SNc and VTA counts.
Neurons were identified as described above and were counted in every
fourth section (40 m). The total neuron number for each nucleus was
obtained by multiplying the neuron count for each nucleus by four.
Individual hypothalamic nuclei were identified based on borders outlined for these structures in the Franklin and Paxinos Brain Atlas. Sections corresponding to Plate 27-54 were included in these counts
(Franklin and Paxinos, 1997).

Using an unbiased stereological method for determining the areal
fraction occupied by an object (in this case TH-positive fibers) as previously described (Gundersen et al., 1988; Jain et al., 2006), TH-positive
fibers were quantified in the dorsal and ventral striatum of 5-month-old
DAT-DTA and control mice. For fiber counts in the dorsal striatum,
three 40 m coronal sections, corresponding to Plates 23, 26, and 29
(Franklin and Paxinos, 1997) were sampled. Two images from each section were used in the analysis for a total of six images per brain. For the
ventral striatum, three 40 m coronal sections corresponding to Plates
21, 23, and 26 were sampled using two images per section for a total of six
images per brain. The sections of striatum used for this analysis were
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obtained from the same brains that provided midbrain sections for
5-month-old SNc and VTA neuron counts.
Evaluation of dopaminergic neurons in the gut was performed on
whole-mount peeled sections of the submucosa from terminal ileum
using TH immunohistochemistry as previously described (Li et al.,
2004). Briefly, intestines were harvested from mice perfused with 4%
paraformaldehyde, fixed flat overnight, rinsed with PBS, peeled, and
prepared for TH immunohistochemistry using diaminobenzidine for
visualization.
Microscopy. All images were captured using an upright microscope
equipped for epifluorescence microscopy (Nikon 80i; CoolSnapES camera). Images were processed using MetaMorph or Adobe Photoshop
software using global adjustments in brightness and contrast.
Biochemistry. Levels of dopamine and its metabolites homovanillic
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined in samples of dorsal striatum using HPLC with electrochemical
detection as previously described (Pehek et al., 1992). Mice were killed by
cervical dislocation. The brain was rapidly removed, frozen on dry ice,
and cut into 1 mm slices using a precooled mouse brain matrix (Stoelting). The dorsal striatum was dissected from slices corresponding to Plate
23–31 in the Franklin and Paxinos Mouse Brain Atlas (Franklin and
Paxinos, 1997).
Statistical analysis. Data are reported as the mean ⫾ SEM. Statistically
significant differences between multiple groups were determined using
two-way ANOVA and Bonferroni post-test. Comparisons between two
groups were determined using the Student’s t test.

Results
At all ages examined, DAT-DTA mice appear healthy and are
indistinguishable from littermate control mice. DAT-DTA mice
were weaned successfully with littermates and did not exhibit any
gross deficits in drinking or feeding behavior. However, at 3–5
months of age, female DAT-DTA mice weighed on average 10%
less than female control mice and at 10 –21 months of age both
male and female DAT-DTA mice weighed ⬃20% less than agematched and sex-matched control mice (Fig. 1 B, C). DAT-DTA
mice survived to 24 months (at which time they were killed),
similar to control mice.
Expression of DTA from the DAT locus results in rapid,
progressive loss of dopaminergic neurons in the SNc and VTA
Loss of TH-positive neurons in the SNc was readily apparent by
P0 in DAT-DTA mice (Figs. 1D, 2A–D). Nissl staining of sections
adjacent to those used for TH labeling show that the loss of THpositive neurons is due to cell loss in the SNc and VTA and not to
loss of TH expression (Fig. 1 E, F ). Quantification of the number
of TH-positive cells revealed a significant 73% decrease in the
number of TH-positive neurons in the SNc of DAT-DTA mice
compared with control mice at P0 (Fig. 1D). The remaining THpositive cells appeared abnormal compared with TH-positive
cells in the SNc of control mice at this stage (Fig. 2 E, F,H ). Remaining neurons had neurites with large varicose swellings (Fig.
2F ). In addition, a large number of cells were swollen and appeared to be disintegrating, suggesting active loss of neurons at
this time point (Fig. 2H ). By 1.5 months of age, TH-positive cell
loss in the SNc of DAT-DTA mice was 90% compared with control mice (Fig. 1D). No additional cell loss relative to control mice
was observed in the SNc through 12 months of age. Loss of THpositive cells was less in the VTA than in the SNc of DAT-DTA
mice at all ages analyzed as has been reported in PD patients and
in several animal models of PD (Dauer and Przedborski, 2003).
This pattern of cell loss in DAT-DTA mice is consistent with
reported lower levels of DAT expression in the VTA compared
with the SNc (Storch et al., 2004). Cell loss in the VTA was also
progressive. In the VTA of DAT-DTA mice, the number of THpositive cells was significantly decreased by 50% at P0 (Figs. 1D,

Figure 2. Loss of TH-positive neurons in the ventral midbrain of DAT-DTA mice. A–D, Fewer
TH-positive neurons are observed in the SNc and VTA of DAT-DTA mice at P0 compared with
control mice. TH-positive neuron loss is less severe in the VTA at this age. E, F, H, At P0, THpositive neurons in the SNc of DAT-DTA mice (F, H ) appear abnormal compared with neurons in
the SNc of control mice (E). TH-positive neurons in the SNc of DAT-DTA mice (F, H ) appear to be
actively degenerating (arrowheads) and have neurites with large varicose swellings (F, arrows).
G, TH-positive neurons in the locus ceruleus (LC) of DAT-DTA mice have a normal appearance.
I–L, At 12 months of age, fewer TH-positive neurons are observed in the SNc and VTA of
DAT-DTA mice compared with control mice. TH-positive neuron loss appears to be more severe
at 12 months compared with P0 in both the SNc and VTA of DAT-DTA mice.

2A–D). By 1.5 months of age, 72% of TH-positive neurons were
lost in the VTA of DAT-DTA mice. The number of TH-positive
neurons in the VTA of DAT-DTA mice further declined by 85%
at 12 months of age (Figs. 1D, 2 I, J ). At all ages examined, re-
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the hypothalamus compared with dopaminergic neurons in the midbrain (Storch
et al., 2004). We counted TH-positive
neurons in the nuclei of the hypothalamus. We found no significant difference
in the number of TH-positive neurons in
the hypothalamus of 5-month-old DATDTA mice compared with control mice
(Fig. 3A). In addition, the morphology of
TH-positive neurons is similar in the hypothalamus of DAT-DTA and control
mice (Fig. 3 B, C).
DAT expression is also reportedly
lower in the gut compared with the brain
(Li et al., 2004). We examined TH-labeled
intrinsic dopaminergic neurons in the terminal ileum of DAT-DTA and control
mice. We found that both the apparent
density and morphological appearance of
TH-labeled dopaminergic neurons in the
terminal ileum was similar in DAT-DTA
mice and control mice (Fig. 3 D, E).

Figure 3. Dopaminergic neurons are normal in the hypothalamus and ileum of DAT-DTA mice. A, Counts of TH-positive neurons
in the nuclei of the hypothalamus reveal no significant differences in neuron number between 5-month-old control mice and
DAT-DTA mice. Pe, Periventricular and paraventricular nucleus; Arc, arcuate nucleus; DM, dorsomedial nucleus; PH, posterior
hypothalamus; PAG, periaqueductal gray; Thal, dorsal thalamus (mean ⫾ SEM, Student’s t test, p ⬎ 0.05; N ⫽ 3 control mice, N ⫽
3 DAT-DTA mice). B, C, TH-positive neurons in the arcuate nucleus of 5-month-old control mice (B) and DAT-DTA mice (C) appear
similar. D, E, TH-positive neurons in the ileum of control mice (D) and DAT-DTA mice (E) appear similar in morphology and density.
Representative images are from one of three control and one of three DAT-DTA mice examined.

maining TH-positive neurons in the SNc and VTA exhibited an
abnormal appearance, including nonsmooth, irregular profiles
and distended neurites with large varicose swellings (Fig. 2 F, H ).
As expected, degeneration was specific to dopaminergic neurons.
TH-positive noradrenergic neurons in the locus ceruleus of
DAT-DTA mice have a normal morphology (Fig. 2G) and do not
appear to be decreased in number compared with control mice,
demonstrating that DTA expression is restricted to dopaminergic
(DAT-positive) neurons.
In contrast to other models of dopaminergic neuron damage
(Breese and Traylor, 1972; Zhou and Palmiter, 1995; Kobayashi
et al., 2004), we did not observe dramatic weight loss and wasting
in DAT-DTA mice (Fig. 1 B, C). Wasting in some of these prior
studies has been attributed to abnormalities in the hypothalamus
and/or damage to dopaminergic neurons in the gastrointestinal
(GI) tract (Kobayashi et al., 2004). In DAT-DTA mice, expression
of the DTA toxin is dependent on DAT-Cre expression. DAT is
expressed at significantly lower levels in dopaminergic neurons of

Locomotor activity is not impaired in
DAT-DTA mice
Locomotor activity in an open field has
been frequently used as a measure of
motor impairment following neurotoxininduced damage to midbrain dopaminergic neurons and in rodent genetic models
of PD (Dunnett and Lelos, 2010; Taylor et
al., 2010). Surprisingly, open-field activity
was not different in DAT-DTA mice compared with control mice at 1.5, 5, 12, or
18 –24 months of age. The total number of
horizontal movements, distance traveled,
and time spent moving were not different
during the 1 h testing period in DAT-DTA
mice compared with age-matched or littermate control mice (Fig. 4A–C). We did
observe an age-dependent decrease in all
three measures of spontaneous locomotor
activity in control mice as reported previously (Gage et al., 1984; Da Silva Costa et
al., 2009) and in DAT-DTA mice.

Performance on the Rotarod is not impaired in DATDTA mice
At 5 (Fig. 4D) and 12 (Fig. 4E) months of age, the time spent on an
accelerating Rotarod was not different in each of five consecutive
trials for DAT-DTA mice compared with control mice. However,
both control mice (Fig. 4G) and DAT-DTA mice (Fig. 4H ) exhibited an age-dependent decrease in the amount of time on the
accelerating Rotarod between 5 and 12 months and between 5
and 18 –24 months. At 18 –24 months of age, performance of
DAT-DTA mice in Trial 1 on the Rotarod was not different from
control mice, suggesting equivalent motor ability in the two
groups (Fig. 4F ). However, 18 –24-month-old DAT-DTA mice
were not able to remain on the accelerating rod for as long as
control mice in the second through fifth trials. The performance
of control mice improved between Trial 1 and Trials 3–5 while
the performance of DAT-DTA mice did not improve after Trial 1.
This result suggests the possibility that the differences between
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Figure 4. DAT-DTA mice do not show motor behavior deficits compared with control mice. A–C, Open-field test: DAT-DTA mice are not significantly different from control mice at any age studied
(mean ⫾ SEM, 2-Way ANOVA, Bonferroni post-test, p ⬎ 0.05). Control mice at 1.5 months exhibit significantly greater locomotor activity compared with 12-month-old control mice (distance, time,
activity, p ⬍ 0.05). DAT-DTA mice an 1.5 months exhibit significantly greater locomotor activity compared with 12-month-old DAT-DTA mice (distance, time, p ⬍ 0.001; activity, p ⬍ 0.01). Control
mice at 1.5 months exhibit significantly greater locomotor activity compared with 18 –24-month-old control mice (activity, p ⬍ 0.05). DAT-DTA mice at 1.5 months exhibit significantly greater
locomotor activity compared with 18 –24-month-old DAT-DTA mice (distance, p ⬍ 0.01; time, p ⬍ 0.001; activity, p ⬍ 0.05). Control mice at 5 months exhibit significantly greater locomotor
activity compared with 12-month-old control mice (distance, time, activity, p ⬍ 0.001). DAT-DTA mice at 5 months exhibit significantly greater locomotor activity compared with 12-month-old
DAT-DTA mice (time, p ⬍ 0.05). Control mice at 5 months exhibit significantly greater locomotor activity compared with 18 –24-month-old control mice (distance, time, activity, p ⬍ 0.001).
Two-way ANOVA, Bonferroni post-test was used for all the above comparisons. Five months, N ⫽ 9 control mice, 8 DAT-DTA mice; 12 months: N ⫽ 9 control mice, 12 DAT-DTA mice; 18 –24 months:
N ⫽ 8 control mice, 6 DAT-DTA mice. D–H, Rotarod test: two-way ANOVA, Bonferroni post-test was used for all the following comparisons. Performance on the Rotarod is not different for DAT-DTA
mice compared with control mice at 5 or 12 months (D, E, p ⬎ 0.05). At 18 –24 months, the performance of DAT-DTA mice is significantly less than control mice in Trials 2–5 (F, *p ⬍ 0.05, **p ⬍
0.01, ***p ⬍ 0.001). At 18 –24 months, the performance of control mice is significantly better in Trials 3–5 compared with Trial 1 (F, Trial 1 vs 3, p ⬍ 0.01; Trial 1 vs 4, p ⬍ 0.001; Trial 1 vs 5, p ⬍
0.01). The performance of 18 –24-month-old DAT-DTA mice is not significantly different between any of the five trials (F, p ⬎ 0.05). Five-month-old control mice perform significantly better than
12 or 18 –24 month control mice. Five month DAT-DTA mice perform significantly better than 12 or 18 –24 month DAT-DTA mice (G, H, *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001). Five months: N ⫽
13 control mice, 12 DAT-DTA mice; 12 months: N ⫽ 9 control mice, 12 DAT-DTA mice; 18 –24 months: N ⫽ 11 control mice, 6 DAT-DTA mice.

DAT-DTA and control mice in Trials 2–5 may be due to a learning impairment in aged DAT-DTA mice. Learning deficits have
been observed in rats depleted of dopamine in the neonatal period (Shaywitz et al., 1976; Whishaw et al., 1987; Archer et al.,
1988).
Sensorimotor function is not impaired in DAT-DTA mice
To determine whether the extensive loss of SNc dopaminergic
neurons alters sensorimotor behavior of adult or aged DAT-DTA
mice, we performed a battery of sensorimotor tests. The pole test
is used to evaluate performance of a complex motor task that
requires skilled forelimb use, strength, and balance (Meredith
and Kang, 2006). At all ages studied, DAT-DTA mice were not
different from control mice either in the time required to turn
around and orient downward on a vertical pole (Fig. 5A) or the

time required to climb down from the pole (Fig. 5B). We did
observe an age-related increase in the time to orient downward and the time to climb down in both control and DATDTA mice.
The platform test evaluates balance and the ledge test evaluates balance and strength. The performance of DAT-DTA mice
(N ⫽ 13 control, 12 DAT-DTA) in the platform and ledge tests
was not different from age-matched control mice at any age studied (data not shown). Tests designed to evaluate the initiation and
speed of movement, including measurement of the time required
to leave the center of a square (18 ⫻ 18 cm; Fig. 5C) or the time
required to reach the top of a screen inclined at 60 or 90° from the
horizontal (data not shown) revealed no significant differences in
performance between DAT-DTA mice and control mice at any
age studied. PD patients exhibit decreased muscle strength that
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Figure 5. Motor behavior and gait are not impaired in DAT-DTA mice compared with control mice. A, B, Pole test: performance in the pole test is not different in DAT-DTA mice compared with
control mice at any age studied (mean ⫾ SEM. Student’s t test). There is an age-dependent decrease in performance on the pole test in both DAT-DTA and control mice (2-Way ANOVA, Bonferroni
post-test). Pole turn around (A): control mice: 5 vs 12 months, Trial 1: p ⬍ 0.001; Trial 2: p ⬍ 0.05; 5 vs 18 –24 months, Trial 1: p ⬍ 0.001; Trial 2: p ⬍ 0.001. DAT-DTA mice: 5 vs 12 months, Trial
1: p ⬍ 0.001; Trial 2: p ⬍ 0.01; 5 vs 18 –24 months, Trial 1: p ⬎ 0.05; Trial 2: p ⬍ 0.05. Pole climb down (B): control mice: 5 vs 12 months, Trial 1: p ⬎ 0.05; Trial 2: p ⬎ 0.05; 5 vs 18 –24 months,
Trial 1: p ⬍ 0.001; Trial 2: p ⬍ 0.01. DAT-DTA mice: 5 vs 12 months, Trial 1: p ⬍ 0.05; Trial 2: p ⬎ 0.05; 5 vs 18 –24 months, Trial 1: p ⬍ 0.05; Trial 2: p ⬎ 0.05. Five months: N ⫽ 13 control mice,
N ⫽ 12 DAT-DTA mice; 12 months: N ⫽ 9 control mice, N ⫽ 12 DAT-DTA mice; 18 –24 months: N ⫽ 8 control mice, N ⫽ 6 DAT-DTA mice. C, Movement-initiation test: movement initiation is not
significantly different in DAT-DTA mice compared with control mice at any age studied (mean ⫾ SEM, Student’s t test, p ⬎ 0.05). Five months: N ⫽ 9 control mice, N ⫽ 7 DAT-DTA mice; 12 months:
N ⫽ 9 control mice, N ⫽ 12 DAT-DTA mice; 18 –24 months: N ⫽ 8 control mice, N ⫽ 6 DAT-DTA mice. D, Inverted screen test: at 5 months, time on an inverted screen is not different in DAT-DTA
mice compared with control mice (mean ⫾ SEM, Student’s t test, p ⬎ 0.05). At 12 and 18 –24 months DAT-DTA mice remain on an inverted screen significantly longer than control mice (mean ⫾
SEM, Student’s t test, *p ⬍ 0.05). There is an age-dependent decrease in performance on the inverted screen test in control mice: Trial 1: 5 vs 12 months, p ⬍ 0.01; 5 vs 18 –24 months, p ⬍ 0.01;
Trial 2: 5 vs 12 months, p ⬎ 0.05; 5 vs 18 –24 months, p ⬍ 0.01 (mean ⫾ SEM, 2-Way ANOVA, Bonferroni post-test). Five months: N ⫽ 9 control mice, N ⫽ 7 DAT-DTA mice; 12 months: N ⫽ 9
control mice, N ⫽ 12 DAT-DTA mice; 18 –24 months, N ⫽ 7 control mice, N ⫽ 6 DAT-DTA mice. E, F, Footprint test: there is no difference in SW or SL between DAT-DTA mice and control mice at any
age studied (mean ⫾ SEM, Student’s t test, p ⬎ 0.05). Three months: N ⫽ 5 control mice, N ⫽ 4 DAT-DTA mice; 4 – 6 months: N ⫽ 8 control mice, N ⫽ 8 DAT-DTA mice; 8 –14 months: N ⫽ 4 control
mice, N ⫽ 3 DAT-DTA mice; 18 months: N ⫽ 6 control mice, N ⫽ 3 DAT-DTA mice.

may be a secondary consequence of decreased activity or a direct
result of dopamine loss (Cano-de-la-Cuerda et al., 2010). We
used the inverted screen test to evaluate muscle strength in DATDTA mice (Tillerson et al., 2002; Fig. 5D). At 5 months of age,
DAT-DTA mice remained on the inverted screen for the same
amount of time as control mice. At 12 and 18 –24 months,

DAT-DTA mice performed better than control mice, remaining on the screen twice as long as control mice. This result
suggests that DAT-DTA mice do not exhibit decreased muscle
strength. We also observed an age-dependent decrease in the
amount of time on the inverted screen for both control and
DAT-DTA mice.
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Gait analysis
Gait analysis has been used previously to
document motor impairment in a number of rodent models, including models of
nigrostriatal dysfunction (Tillerson et al.,
2002; Byler et al., 2009; Taylor et al.,
2010). Our analysis revealed no differences in SW (Fig. 5E) or SL (Fig. 5F ) in
DAT-DTA mice compared with agematched control mice at any age studied.
In addition, measures of paw length, TS,
and ITS were not different between DATDTA mice and control mice at any age
studied (data not shown).
Marked reduction in TH-positive fiber
density in the dorsal and ventral
striatum of DAT-DTA mice
The absence of motor behavior deficits
in DAT-DTA mice, despite near complete loss of SNc dopaminergic neurons,
prompted us to evaluate dopaminergic innervation of the striatum. We examined
TH-positive fibers in the dorsal and ventral striatum of DAT-DTA mice to determine whether dopaminergic cell loss in
the SNc and VTA is accompanied by loss
of striatal dopaminergic afferents. At P0,
TH-positive striatal afferents are greatly
reduced in the dorsal striatum of DATDTA mice compared with control mice
(Fig. 6 A, B). At this age, fiber density is
also reduced in the ventral striatum of
DAT-DTA mice, but the reduction in the Figure 6. Loss of TH-positive fibers in the dorsal and ventral striatum of DAT-DTA mice. A, B, At P0, TH-positive fibers are
ventral striatum appears less severe than decreased in the dorsal striatum of DAT-DTA mice compared with control mice. TH-positive fiber density is less affected in the
the reduction in the dorsal striatum (Fig. ventral striatum of DAT-DTA mice (B, arrow). The white dotted line in A and B outlines the area of the dorsal and ventral striatum.
6B, arrow). TH-positive fiber density ap- C, Quantification of TH-positive fiber density in the striatum of 5-month-old mice reveals a significant decrease in fiber density in
pears to be further decreased in the dorsal both the dorsal and ventral striatum of DAT-DTA mice compared with control mice (mean ⫾ SEM, Student’s t test, ***p ⬍ 0.001).
striatum of DAT-DTA mice at 5 (Fig. N ⫽ 3 control mice, N ⫽ 3 DAT-DTA mice. D–G, Representative images used for quantifying fiber density showing decreased
6 D, E) and 12 months of age (data not TH-positive fiber density in both the dorsal and ventral striatum of DAT-DTA mice compared with control mice.
shown), which is consistent with the inthe dopamine metabolites HVA and DOPAC in the dorsal striacreased loss of dopaminergic neurons from the SNc after P0 (Fig.
tum of DAT-DTA and control mice. Dopamine, DOPAC, and
1D). We quantified the areal fraction of TH-positive fibers in the
HVA are significantly decreased in the dorsal striatum of DATdorsal and ventral striatum of 5-month-old DAT-DTA and conDTA mice compared with control mice at 2, 5–7, and 12–24
trol mice using an unbiased stereological method as previously
months of age (Fig. 7A). The ratio of DOPAC to dopamine was
described (Gundersen et al., 1988; Jain et al., 2006). At 5 months
not different in DAT-DTA mice compared with control mice at
of age, TH-positive fiber density is decreased by ⬃93% in the
any age studied (Fig. 7B). At 2 months of age, the ratio of HVA to
dorsal striatum of DAT-DTA mice compared with control mice
dopamine was not significantly different in DAT-DTA mice
(Fig. 6C–E). At this age, TH-positive fiber density is decreased by
compared with control mice (Fig. 7C). However, at 5–7 and
⬃58% in the ventral striatum of DAT-DTA mice compared with
12–24 months of age, the ratio of HVA to dopamine was significontrol mice (Fig. 6C, F, G). The more severe fiber loss in the
cantly increased in DAT-DTA mice compared with control mice.
dorsal striatum compared with the ventral striatum ( p ⬍ 0.001)
Dopamine depletion in the dorsal striatum of DAT-DTA mice
is consistent with the greater magnitude of SNc cell loss comis nearly complete (97%) at 2 months, suggesting that dopaminepared with VTA cell loss at this age (Fig. 1D).
independent mechanisms could be responsible for normal motor
behavior in DAT-DTA mice. To determine whether the normal
Biochemical analysis reveals a marked reduction of striatal
motor behavior of DAT-DTA mice is dependent on residual dodopamine in DAT-DTA mice
pamine, we treated 12-month-old male and female DAT-DTA
Compensatory mechanisms that maximize dopaminergic transand control mice with the dopamine receptor antagonist halomission have been identified following damage to the nigrostriaperidol and evaluated motor behavior. As expected, haloperidol
tal dopaminergic pathway (Zigmond et al., 1984, 1990). These
treatment resulted in a significant decrease in the locomotor acinclude increased dopamine synthesis and increased dopamine
tivity of 12-month-old control mice in the open-field test comrelease (suggested by an increase in the ratio of dopamine metabolites to dopamine). We used HPLC to quantify dopamine and
pared with vehicle (DMSO)-treated control mice (Fig. 8A).
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old DAT-DTA mice and control mice with L-DOPA (25 mg/kg)
and measured locomotor activity. This dose of L-DOPA did not
alter the locomotor activity of control mice in the open-field test
compared with vehicle-treated control mice (Fig. 8B). The locomotor activity of L-DOPA-treated DAT-DTA mice was significantly increased compared with L-DOPA-treated control mice
(Fig. 8B). The observed increase in locomotor activity in DATDTA mice compared with control mice in response to L-DOPA
suggests that striatal dopamine receptors are functionally sensitized in DAT-DTA mice. This sensitization likely contributes to
the preservation of motor behavior observed in these mice.
Movement initiation was not altered in either DAT-DTA mice or
control mice in response to L-DOPA (Fig. 8B).
To determine whether increased expression of dopamine receptors contributes to functional sensitization, we evaluated the
expression of dopamine receptors in 12-month-old DAT-DTA
mice using qRT-PCR. Our analysis shows no change in the expression of either D1 or D2 dopamine receptors in the dorsal
striatum of DAT-DTA mice compared with control mice (data
not shown). The observed functional sensitization in response to
L-DOPA may be a result of mechanisms that regulate the translation of dopamine receptors, the post-translational modification of receptors, or receptor trafficking. Additional studies will
be required to evaluate the contribution of these potential
changes to sensitization.

Discussion

Figure 7. Dopamine, DOPAC, and HVA are depleted in the dorsal striatum of DAT-DTA mice.
A, Dopamine, DOPAC, and HVA are decreased in the dorsal striatum of DAT-DTA mice compared
with control mice at all ages studied (mean ⫾ SEM, Student’s t test, control vs DAT-DTA at each
time point; *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001). B, The ratio of DOPAC to dopamine is not
significantly different between DAT-DTA mice and control mice at any age studied (mean ⫾
SEM, Student’s t test, p ⬎ 0.05). C, The ratio of HVA to dopamine is significantly increased in
DAT-DTA mice compared with control mice at 5–7 and 12–24 months of age (mean ⫾ SEM,
Student’s t test, **p ⬍ 0.01). Two months: N ⫽ 5 of each genotype; 5–7 months: N ⫽ 3 of each
genotype; 12–24 months: N ⫽ 5 control mice, 4 DAT-DTA mice.

Haloperidol-treated control mice were similarly impaired in the
movement-initiation test (Fig. 8A) and the catalepsy test (data
not shown) compared with vehicle-treated control mice. The
performance of 12-month-old haloperidol-treated DAT-DTA
mice was not different from haloperidol-treated littermate control mice in the open-field test (Fig. 8A), the movement-initiation
test (Fig. 8A), or the catalepsy test (data not shown). These results
indicate that maintenance of normal motor behavior in DATDTA mice is dependent on the small amount of remaining striatal
dopamine (3% of control; Fig. 7A) in DAT-DTA mice.
Previous studies have shown that dopamine receptor agonists
induce an exaggerated increase in locomotor activity in animals
with nigrostriatal damage. The increased activity in response to
dopamine agonists observed in injured animals is reportedly due
to sensitization of striatal dopamine receptors (Zigmond and
Stricker, 1980; Breese et al., 1985; Brotchie and Fitzer-Attas,
2009). To gain insight into the mechanism by which motor behavior is preserved in DAT-DTA mice, we treated 6 –7-month-

DTA expressed from the DAT locus produces a substantial and
reproducible loss of SNc dopaminergic neurons and striatal dopamine in DAT-DTA mice without the systemic toxicity, dosing
limitations, or lack of specificity inherent in models using neurotoxins to destroy dopaminergic neurons (Blandini and Armentero, 2012). Despite loss of 90% of SNc dopaminergic neurons,
dysfunction of surviving neurons (as inferred from degenerative
morphological changes), and depletion of 97% of striatal dopamine, we were not able to detect motor behavior defects in DATDTA mice using behavior tests that have been used previously to
demonstrate motor dysfunction in other models of nigrostriatal
damage (Meredith and Kang, 2006; Byler et al., 2009; Taylor et al.,
2010). Importantly, we were able to detect an age-dependent
decline in motor performance in both control and DAT-DTA
mice, demonstrating that our testing methods are sufficient to
detect motor dysfunction. Our results indicate that preserved
motor function in DAT-DTA mice is dependent on residual dopamine. Other, nondopaminergic mechanisms may also contribute to the maintenance of motor function in DAT-DTA mice, but
such mechanisms are insufficient to maintain normal motor behavior when dopaminergic transmission is blocked by haloperidol. Previous studies in which dopaminergic neurons have been
destroyed by administration of toxins to adult animals have
found motor behavior deficits with far less severe SNc neuron
loss and striatal dopamine depletion than those seen in DATDTA mice (Bové and Perier, 2012). However, the majority of SNc
dopaminergic neurons (⬎70%) are lost in DAT-DTA mice during prenatal development. Our results show that the nigrostriatal
dopaminergic pathway has a significant capacity to compensate
for damage sustained during prenatal development. The remarkable preservation of motor function in DAT-DTA mice that occurs in the absence of growth retardation and nonspecific damage
to nondopaminergic pathways suggests that additional mechanisms of plasticity may be induced when damage occurs in developing animals. Identification of the molecular mechanisms that
underlie motor behavior sparing in DAT-DTA mice may suggest
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Figure 8. DAT-DTA mice are sensitive to haloperidol and hypersensitive to L-DOPA. A, Haloperidol (1 mg/kg) significantly decreases locomotor activity in both DAT-DTA mice and control mice at
12 months of age. Locomotor activity is not significantly different in haloperidol-treated DAT-DTA mice compared with haloperidol-treated control mice. The time required to exit an 18 ⫻ 18 cm
square is significantly increased in haloperidol-treated DAT-DTA mice and haloperidol-treated control mice compared with vehicle-treated control mice. Exit time is not significantly different in
haloperidol-treated DAT-DTA mice compared with haloperidol-treated control mice. Mean ⫾ SEM, Student’s t test, control vs DAT-DTA, *p ⬍ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001. Control mice/DMSO,
N ⫽ 2; control mice/haloperidol, N ⫽ 7; DAT-DTA mice/haloperidol, N ⫽ 7. B, The locomotor activity of L-DOPA-treated control mice is not significantly different from vehicle-treated control mice.
The locomotor activity of L-DOPA-treated DAT-DTA mice is significantly increased compared with L-DOPA-treated control mice. The time required to exit an 18 ⫻ 18 cm square is not significantly
different in L-DOPA-treated DAT-DTA mice compared with L-DOPA-treated control mice. Mean ⫾ SEM, Student’s t test, control vs DAT-DTA, *p ⱕ 0.05, **p ⬍ 0.01, ***p ⬍ 0.001. Control
mice/vehicle, N ⫽ 4; control mice/L-DOPA, N ⫽ 5; DAT-DTA mice/L-DOPA, N ⫽ 7.

novel strategies for treating PD or for improving current
therapies.
Studies in which prenatal exposure to a neurotoxin was used
to damage the nigrostriatal system have found that less severe
damage, compared with that seen in DAT-DTA mice, results in
defects in motor performance. For example, prenatal administration of MPTP reduces striatal dopamine by ⬃14% and results in
decreased spontaneous locomotion (Muthian et al., 2010). Prenatal administration of lipopolysaccharide produces a moderate
decrease in SNc dopaminergic neurons (⬃30%; Ling et al., 2002,
2009; Carvey et al., 2003) and results in decreased locomotion in
the open field and an increased number of skips in the beamwalking test (Bakos et al., 2004). These findings are consistent
with the idea that damage to dopaminergic neurons during prenatal development can result in motor behavior defects in adult
animals. A much greater percentage of SNc dopaminergic neurons are destroyed during prenatal development in DAT-DTA
mice. A greater magnitude of neuron loss may be required to
induce mechanisms of compensation. It is also possible that toxicity to the mother or other unknown effects of the toxin in the
fetus could affect motor behavior in animals treated prenatally
with toxins.
Moderate feeding and motor behavior deficits occur in rats in
which 6-OHDA is used to damage dopaminergic neurons during
early postnatal development (Breese et al., 2005). Adult rats sustaining ⬎95% depletion of striatal dopamine following intracerebralventricular or intranigral administration of 6-OHDA

exhibit adipsia, aphagia, and akinesia (Ungerstedt, 1971; Zigmond and Stricker, 1973; Marshall et al., 1974). Although rats
treated with intracerebralventricular 6-OHDA as neonates (P3)
sustain comparable depletion of striatal dopamine as adulttreated rats, they exhibit much less severe feeding and motor
behavior defects. Locomotor behavior is reportedly increased
(Shaywitz et al., 1976; Erinoff et al., 1979, 1984; Archer et al.,
1988) or decreased (Smith et al., 1973) in adult rats treated with
6-OHDA as neonates. In addition, defects in skilled forearm and
tongue use have been observed in these rats (Whishaw et al.,
1987). In contrast to neonatal-treated 6-OHDA rats that have
some motor behavior deficits, we were not able to detect any
deficits in motor behavior in DAT-DTA mice that sustained
comparable depletion of striatal dopamine. This difference may
be related to the time course of SNc cell damage in the two models, to species differences, or to other effects of the toxin. In
addition to dopaminergic neurons, 6-OHDA also damages noradrenergic neurons (Ungerstedt, 1968). Damage to noradrenergic neurons alone increases locomotor behavior (Smith et al.,
1973). Although, desmethylimipramine (DMI) is routinely administered with 6-OHDA to minimize damage to noradrenergic
neurons, DMI is not completely effective in preventing damage to
noradrenergic neurons (Breese and Traylor, 1971; Castañeda et
al., 1990). In addition, mice treated with 6-OHDA at early postnatal stages show marked growth retardation, which could impact motor behavior (Breese and Traylor, 1972). Our data show
normal motor behavior in a mouse model in which substantial
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damage specifically to dopaminergic neurons is sustained during
prenatal development in the absence of adverse effects on general
health.
Rats treated with 6-OHDA as neonates are resistant to haloperidol treatment in adulthood, suggesting that nondopaminergic
systems are compensating for the loss of dopamine to maintain
normal motor behavior in these rats (Bruno et al., 1985; Duncan
et al., 1987; Weihmuller and Bruno, 1989). In contrast, our results indicate that with comparable depletion of striatal dopamine, residual dopamine is responsible for the maintenance of
normal motor behavior in DAT-DTA mice. It is surprising that
normal motor behavior in DAT-DTA mice is dependent on residual dopamine. TH-positive fibers are virtually absent in the
striatum of adult DAT-DTA mice and striatal dopamine is decreased by 97%, indicating nearly complete depletion of dopamine. Preservation of motor behavior following partial damage
to the nigrostriatal system is thought to be due to adaptations in
residual dopaminergic terminals, such as increased dopamine
synthesis and release and attenuated dopamine reuptake (Zigmond et al., 1984, 1990). In addition, changes in postsynaptic
striatal neurons can also maximize dopaminergic transmission
when dopamine levels are severely depleted.
Increased dopamine release is reflected by an increase in the
ratio of dopamine metabolites to dopamine, particularly the
HVA/dopamine ratio. DAT-DTA mice have a significantly
greater HVA/dopamine ratio, which is consistent with the hypothesis that maintenance of motor function in DAT-DTA mice
is dependent upon mechanisms that maximize the efficiency
of residual dopamine. However, dopamine-dependent mechanisms that preserve normal motor behavior in animals with partial nigrostriatal damage are reportedly limited. Previous studies
indicate that these mechanisms are only effective when ⱖ5–10%
of dopaminergic terminals remain in the striatum (Reader and
Dewar, 1999). In addition, the nigrostriatal system is more susceptible to toxin-induced damage in aged animals and compensatory mechanisms that maximize dopamine function are
attenuated in aged animals (Ovadia et al., 1995; Thiruchelvam et
al., 2003; Collier et al., 2007, 2011; Peng et al., 2007). It is therefore
surprising that no motor defects are observed in DAT-DTA mice,
even at 18 –24 months of age, and that aged DAT-DTA mice are
sensitive to haloperidol, suggesting that compensatory mechanisms that rely on residual dopamine are intact even in aged
DAT-DTA mice. Our results further indicate that the mechanism
underlying preservation of motor behavior in DAT-DTA mice
involves functional sensitization of dopamine receptors.
Interestingly, developmental elimination of dopaminergic
transmission by deletion of TH or D1 and D2 dopamine receptors results in more severe behavior deficits than destruction of
dopaminergic neurons in DAT-DTA mice. Dopamine-deficient
mice are hypoactive, exhibit severe growth retardation, and die
during the third postnatal week (Zhou and Palmiter, 1995). Mice
in which both the D1 and D2 dopamine receptors are deleted
have a similar phenotype to dopamine-deficient mice and also
die in the third postnatal week (Kobayashi et al., 2004). Premature death of D1/D2-null mice is thought to be due to peripheral
GI defects that result in a failure to thrive and severe growth
retardation. In contrast, DAT-DTA mice are generally healthy
and appear to grow and develop normally. The absence of severe
growth retardation in DAT-DTA mice may be due to lower DAT
expression and thus lower DAT-CRE activity in peripheral dopaminergic neurons, which results in less DTA-mediated cell damage in the GI system (Li et al., 2004). Our observation that
intrinsic dopaminergic neurons in the terminal ileum appear
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similar in DAT-DTA mice and control mice is consistent with
this possibility. In addition, we observed no significant loss of
dopaminergic neurons in the hypothalamus of DAT-DTA mice
compared with control mice. Since DAT expression is also reported to be significantly lower in hypothalamic dopaminergic
neurons compared with midbrain dopaminergic neurons
(Storch et al., 2004), this observation also supports the hypothesis
that expression of the DTA toxin is lower in dopaminergic neurons with low DAT expression. The olfactory bulbs contain a
large number of dopaminergic neurons in which DAT expression
is also reportedly low (Cerruti et al., 1993; Fujita et al., 1993). It
will be interesting to determine whether these neurons are altered
in DAT-DTA mice. It is also possible that dopaminergic transmission is more significantly impaired in dopamine-deficient
and D1/D2-null mice compared with DAT-DTA mice. Studies
using microdialysis show that the decrease in extracellular dopamine concentration is not as severe as the decrease in tissue dopamine following neonatal 6-OHDA treatment (Castañeda et al.,
1990). Therefore, although striatal dopamine is decreased by 97%
in DAT-DTA mice, extracellular dopamine may not be entirely
depleted in these mice.
Our studies reveal remarkable preservation of motor behavior
in mice with severe loss of SNc dopaminergic neurons and nearly
complete depletion of striatal dopamine. The observation that
preserved motor behavior depends on mechanisms that require
intact dopaminergic transmission in aged DAT-DTA mice suggests even greater plasticity of the nigrostriatal dopaminergic
pathway than previously thought. The DAT-DTA mouse is a
novel model for studying the behavioral effects of dopamine depletion in the absence of motor impairment or growth retardation. For example, studies examining the role of dopaminergic
pathways in addiction and in the regulation of circadian rhythm
use behavioral assays, such as conditioned place preference and
voluntary wheel running, that depend on intact motor function.
Interpretation of these assays is complicated by impaired motor
performance in neurotoxin models of dopaminergic neuron
damage. The DAT-DTA mouse provides an opportunity to evaluate the effects of damage to dopaminergic pathways in the absence of motor dysfunction.
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